Protein G Chromatography eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
Immunogen
This monoclonal antibody is generated from mice immunized with a KLH conjugatedsynthetic peptide corresponding to sequences in Tyr1234/1235 region of human Met andresidues both Tyr1234 and Tyr1235 are phosphorylated.
MET
Reactivity: Human, Mouse, Rat
WB, ELISA, IF, ICC
Host: Rabbit
Polyclonal
unconjugated
Application Notes
ELISA: 1/1,000. Western Blot. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Format
Liquid
Concentration
0.25 mg/mL
Buffer
PBS with 0.09 % (W/V) Sodium Azide as preservative, 0.09 % (W/V) Sodium Azide
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C/-20 °C
Storage Comment
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer. Avoid repeated freezing and thawing. Shelf life: one year from despatch.
AUTS9 antibody, HGFR antibody, RCCP2 antibody, c-Met antibody, AI838057 antibody, HGF antibody, Par4 antibody, Hgfr antibody, c-met antibody, MET antibody, C-MET antibody, met antibody, met-A antibody, MET proto-oncogene, receptor tyrosine kinase antibody, met proto-oncogene antibody, MET proto-oncogene, receptor tyrosine kinase L homeolog antibody, MET antibody, Met antibody, met.L antibody
Background
MET/HGFR is a receptor for hepatocyte growth factor, with tyrosine-protein kinase activity. The MET/HGFR Type I membrane protein contains 1 Sema domain and consists of a heterodimer formed of an alpha chain (50 kDa) and a beta chain (145 kDa) which are disulfide linked. In the fully processed c-Met product, the alpha subunit is extracellular, and the beta subunit has extracellular, transmembrane, and tyrosine kinase domains as well as sites of tyrosine phosphorylation. Two isoforms for the protein have been described. Activation of MET after rearrangement with the TPR gene produces an oncogenic protein. MET is overexpressed in a significant percentage of human cancers and is amplified during the transition between primary tumors and metastasis. Defects in MET are a cause of hereditary papillary renal carcinoma (HPRC), also known as papillary renal cell carcinoma 2 (RCCP2). HPRC is a form of inherited kidney cancer characterized by a predisposition to develop multiple, bilateral papillary renal tumors. The pattern of inheritance is consistent with autosomal dominant transmission with reduced penetrance.Synonyms: HGF/SF receptor, Hepatocyte growth factor receptor, MET, Met proto-oncogene tyrosine kinase, Scatter factor receptor, c-Met